FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:305-307 January 25, 2001 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Saltz, L. B. PubMed Citation

To the Editor: The study by Saltz et al. (Sept. 28 issue)¹ leaves unanswered questions regarding the toxicity and dose intensity of the combination of irinotecan, fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer. The authors indicate that "the median relative intensity of the dose of irinotecan . . . was similar in the group given irinotecan alone and the group given irinotecan, fluorouracil, and leucovorin." However, the median relative intensity of the dose of fluorouracil was lower in the triple-drug combination than in the two-drug combination.

These points lead us to ask the following: During cycle 1 . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Brandi, G., Dabard, J., Raibaud, P., Di Battista, M., Bridonneau, C., Pisi, A. M., Labate, A. M. M., Pantaleo, M. A., De Vivo, A., Biasco, G. (2006). Intestinal Microflora and Digestive Toxicity of Irinotecan in Mice. Clin. Cancer Res. 12: 1299-1307 [Abstract] [Full Text]  
• Goldberg, R. M., Kaufmann, S. H., Atherton, P., Sloan, J. A., Adjei, A. A., Pitot, H. C., Alberts, S. R., Rubin, J., Miller, L. L., Erlichman, C. (2002). A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. Ann Oncol 13: 1674-1680 [Abstract] [Full Text]